GLP-1 Prior Authorization: Requirements and How to Appeal

If you have been trying to get your insurance to cover a GLP-1 medication, you have probably encountered prior authorization. It is the requirement that your provider submit clinical documentation to your insurer or pharmacy benefit manager before the insurance will approve and pay for the prescription. It is frustrating, it adds weeks to the timeline, and it sometimes results in denial.

But it is not a personal judgment. It is a standard insurance process. And there are concrete steps you can take to improve the odds of approval, and clear appeal rights if the insurer says no.

Here is what you need to know.

What prior authorization actually is

Prior authorization (often abbreviated PA) is a utilization management process where your insurer or pharmacy benefit manager (PBM) requires your prescribing provider to submit clinical documentation justifying the prescription before they will approve coverage.

GLP-1 medications go through prior authorization because they are expensive (brand-name semaglutide costs hundreds of dollars per month for your insurance to cover, even at a tier with a copay). Insurers use prior authorization to ensure that the medication is being prescribed for clinically appropriate reasons, and that cheaper alternatives have been tried first.

Prior authorization is not a judgment about your willpower or your commitment. It is a formulary management tool, and it applies to millions of prescriptions across all drug categories every year.

What GLP-1 prior authorization typically requires

Insurers do not have a single standardized PA form. Each plan has its own requirements, and requirements vary between semaglutide and tirzepatide. But most plans require these pieces of clinical information:

1. Documented body mass index (BMI) Your BMI must be documented in your provider’s medical record from a recent visit. Most plans require BMI of 30 or higher, or 27 or higher if you have a qualifying comorbidity. Self-reported weight or BMI is not sufficient; it must come from an office visit or telehealth evaluation.

2. List of comorbidities If your BMI is 27-29 (below the 30 threshold), the plan typically requires documentation of at least one qualifying comorbidity. Common qualifying conditions include type 2 diabetes, hypertension, hyperlipidemia, cardiovascular disease, sleep apnea, fatty liver disease, or osteoarthritis.

3. Documentation of prior lifestyle intervention Many plans require evidence that the patient has attempted diet and exercise before the insurer will cover medication. Some plans ask for informal documentation (a note in the chart that the patient has been trying diet and exercise). Other plans require 3-6 months of documented weight loss attempts, or referral to a dietitian or fitness program.

4. Confirmation of no contraindications The PA submission must document that the patient does not have contraindications to GLP-1 medications. The main contraindications are: personal or family history of medullary thyroid carcinoma (MTC), family history of MEN2 syndrome, or history of acute or chronic pancreatitis.

5. Sometimes: prior medication history Some plans ask whether the patient has previously tried and failed other weight loss medications, such as phentermine or topiramate. This is not always required, but some plans want to see it.

6. Provider’s clinical notes The PA submission should include a brief clinical justification from the provider explaining why the medication is appropriate for this patient’s health situation and goals.

Who submits the prior authorization

Your prescribing provider’s office submits the PA, not you. But the provider needs your authorization and insurance information to do so.

When you are prescribed GLP-1 medication, the provider’s staff will need to contact your insurance or PBM to initiate the PA. This requires your insurance card information and your verbal or written permission. Most providers have staff dedicated to managing prior authorizations; it is a routine part of their workflow.

The insurer or PBM sends the PA form to the provider’s fax or patient portal. The provider’s staff gathers the required documentation (usually from your medical record and any recent labs) and submits it.

How long does the process take

Here is the typical timeline from the moment you receive a prescription to the moment you can pick up the medication at the pharmacy:

Total timeline if approved on first submission: 1-5 days for submission + 3-10 days for decision = typically 2-3 weeks from the moment you get the prescription to the moment you receive medication.

Total timeline if denied and appealed: Add another 5-15 days for the appeal process. Total: 4-8 weeks is realistic.

Why prior authorization gets denied

Denial rates for first-submission GLP-1 prior authorizations are substantial. Provider offices report that 30-50% of first-submission PAs are denied^[1], though the exact rate varies by insurer and plan.

The good news: most denials are not because the patient does not qualify. They are because documentation is incomplete.

The most common denial reasons:

Missing or incomplete BMI documentation The insurer receives the PA but the documented BMI is missing, outdated, or unclear. If the patient has not had a recent office visit with a recorded height and weight, the insurer will deny for “insufficient evidence of qualifying BMI.”

Missing comorbidity documentation The patient has hypertension or diabetes, but these are not explicitly documented in the medical record that was submitted with the PA. The insurer denies because they cannot verify the comorbidity from the submitted paperwork.

No documentation of prior lifestyle intervention The plan requires evidence of diet and exercise attempts, but the provider did not include this in the PA submission. The insurer denies for “failure to document conservative treatment attempt.”

Formulary exclusion Some plans have a categorical exclusion for weight management medications. If the patient’s plan excludes weight management GLP-1s entirely, the PA will be denied regardless of clinical appropriateness. (This is different from a clinical denial; the patient simply does not have coverage for this indication.)

Diagnostic code mismatch The provider submitted the PA using the diagnosis code for obesity or weight management, but the patient’s plan only covers GLP-1s for type 2 diabetes or cardiovascular disease. The insurer denies because the diagnosis code does not match a covered indication.

The appeal process

If your initial PA is denied, you have the right to appeal. The appeal process varies by state and plan, but here is the standard structure:

First-level appeal (Internal Review)

Your provider’s office can request a first-level appeal. This is a review of the same PA by a different reviewer within the insurance company. The appeal is typically submitted within 30-60 days of the denial.

The first-level appeal should include:

• All original PA documentation
• Strengthened or clarified documentation addressing the reason for denial
• A letter from the provider explaining the clinical necessity
• Supporting peer-reviewed literature (such as data from the STEP or SURMOUNT clinical trials)

Decision time: 5-10 business days for urgent appeals, 15-30 business days for standard appeals.

Success rate: Many providers report that first-level appeals succeed 40-60% of the time when documentation gaps are filled.

Second-level appeal (Clinical Review)

If the first-level appeal is denied, you can request a second-level appeal. This goes to a medical director or clinical review officer at the insurance company. The submission window is typically 30-60 days after the first denial.

Decision time: 30 business days.

External Review

If the second-level appeal is denied (or if state law allows you to request external review earlier), you have the right to request an independent external review. This is conducted by an outside medical review organization, not by the insurer. External reviews are free to the patient and are required by most state laws.

The external reviewer (typically a provider) examines the clinical case and the denials. Decisions often take 30-60 days. External reviews reverse denials in a meaningful percentage of cases, especially when new clinical information or stronger documentation is included.

Tips for improving your chances of PA approval

If you are about to start the prior authorization process, here are concrete steps you can take to improve the odds:

1. Make sure your BMI is documented Before submitting the PA, ask your provider’s office whether your BMI is documented in your recent medical records from an office visit. If not, schedule a brief visit (telehealth is fine) to get measured. This is the single most common reason for initial denial.

2. Ensure all comorbidities are documented If you have hypertension, diabetes, sleep apnea, high cholesterol, or any other condition that qualifies, make sure these diagnoses are in your medical record. Do not rely on the provider to infer it. If a comorbidity is not explicitly documented, ask the provider to add it to your chart before the PA is submitted.

3. Document prior lifestyle intervention If your plan requires evidence of diet and exercise attempts, provide whatever evidence you can. This does not need to be formal. A documented conversation in the chart that says, “Patient reports three months of documented calorie restriction and regular exercise with minimal weight loss; discussed GLP-1 medication as an option” is usually sufficient. Ask your provider to include this in the PA submission.

4. Ask the provider to include clinical literature Request that the provider’s office include a one-page summary or printout of peer-reviewed evidence supporting GLP-1 medications for your situation. The STEP trials^[2] (semaglutide for weight management) and SURMOUNT trials^[3] (tirzepatide for weight management) are the most relevant. This small addition often tips the scales from denial to approval.

5. Request expedited review if clinically justified If you have a serious health condition or time-sensitive medical reason for starting the medication, ask the provider to request expedited review. This can reduce the decision timeline from 7-10 days to 3-5 days.

When prior authorization will not work

There are situations where the PA process is unlikely to succeed, no matter how complete your documentation is.

Categorical formulary exclusion for weight management If your plan explicitly excludes GLP-1 medications for weight management (some plans do), prior authorization cannot override this. The medication is simply not covered for that indication. Your options are: (1) ask whether the medication can be prescribed under a different indication if you have diabetes, (2) appeal on medical necessity grounds (which may succeed in some states), or (3) pursue cash pay.

No qualifying diagnosis in your plan’s covered indications If your plan only covers GLP-1s for type 2 diabetes or cardiovascular disease, and you do not have either condition, prior authorization based on weight management alone will not succeed.

Insurance lapse If your insurance lapses or changes during the PA process, the decision may become void. You will need to resubmit with your new insurance information.

When cash-pay makes more sense

Given the timeline and denial rates, some patients find that paying out of pocket is faster and more predictable than waiting for insurance approval.

Transformation Health programs are all-inclusive and cost $249 to $339 per month, depending on the medication and formulation. This includes:

• Compounded medication (prepared by a US-licensed pharmacy)
• Medical oversight from a licensed provider
• Any required lab work
• Coaching and nutrition guidance
• No hidden fees
• Cancel anytime

With Transformation Health, there is no prior authorization process. You complete an online assessment, a provider reviews your health history, and if the medication is appropriate, you receive a provider decision within 24-48 hours. Medication ships within 1-3 business days.

The trade-off is straightforward: out-of-pocket cost vs. the possibility (not certainty) of insurance coverage after a 3-8 week wait.

For patients whose insurance has denied them before, whose plans exclude weight management medications, or who are frustrated with the timeline, cash-pay is often the more predictable path.

FAQ

Q: How long does prior authorization for GLP-1 take?

A: The process typically takes 1-5 business days for your provider to gather and submit documentation, then 3-10 business days for the insurer’s initial decision. If approved on first submission, you can proceed to the pharmacy within 2-3 weeks of initiating the process. Denials extend the timeline; a first-level appeal adds another 5-10 business days. Total from start to covered prescription: often 3-6 weeks if approved, longer if appealed.

Q: What is the most common reason GLP-1 prior authorization is denied?

A: Incomplete or missing documentation is the most common reason. Insurers require specific clinical evidence: documented BMI from a recent visit, comorbidity diagnoses in the medical record, and often documentation of prior lifestyle intervention. When these are not explicitly included in the PA submission, the insurer denies due to insufficient evidence rather than because the patient does not qualify.

Q: Should I appeal a GLP-1 PA denial?

A: Yes, in most cases it is worth appealing. First-submission denials often occur due to documentation gaps rather than categorical exclusion. A first-level appeal with strengthened documentation (explicit BMI documentation, comorbidity records, clinical notes) succeeds in many cases. Ask your provider’s office to include supporting clinical literature with the appeal.

Q: What if my insurance categorically excludes weight management medications?

A: A categorical formulary exclusion for weight management drugs cannot be overridden through prior authorization. In this case, your options are: (1) explore whether the medication can be prescribed under a different covered indication such as type 2 diabetes if applicable, (2) appeal on medical necessity grounds, (3) pay out of pocket with a cash-pay program.

Citations

[1] Provider and patient survey data on GLP-1 prior authorization denial rates. Per medical evidence compiled from multiple health plan utilization management reports, 2024-2026.

[2] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/

[3] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/